Management of Tinea Pedis in Pediatric Patients

First-Line Topical Treatment

The American Academy of Pediatrics recommends topical terbinafine 1% cream applied twice daily for 1 week for interdigital disease (or 2 weeks for plantar involvement) as the first-line treatment, providing superior efficacy with the shortest treatment duration 1, 2
Terbinafine 1% cream achieves faster clinical resolution than other topical agents and allows once-daily dosing with shorter treatment duration 1, 2
Ciclopirox olamine 0.77% cream/gel applied twice daily for 4 weeks achieves approximately 60% clinical and mycological cure at end of treatment, increasing to 85% two weeks post-treatment 1, 2
Clotrimazole 1% cream applied twice daily for 4 weeks is less effective than terbinafine but widely available over-the-counter 1

The American Academy of Pediatrics recommends reserving oral antifungals for extensive disease, failed topical therapy, concomitant nail involvement, or immunocompromised patients 2, 3
Oral terbinafine 250 mg once daily for 1-2 weeks (standard adult dosing; weight-based dosing for younger children) is the first-line systemic treatment 1, 2, 3
Itraconazole 100 mg daily for 2 weeks or pulse dosing 200-400 mg daily for 1 week per month has similar mycological efficacy to terbinafine but may have slightly higher relapse rates 1, 2, 3

Prevention strategies, such as applying foot powder after bathing, thoroughly drying between toes after showering, and changing socks daily, are critical to reduce recurrence rates and should be implemented alongside pharmacologic treatment 1, 2, 3
Covering active foot lesions with socks before wearing underwear to prevent spread to groin (tinea cruris) is recommended 1, 2
Treating all infected family members simultaneously to prevent reinfection is recommended 2, 3

The American Academy of Pediatrics recommends requiring a minimum of 72 hours of antifungal therapy before return to contact sports 2
Athletes (especially swimmers and marathon runners) have documented infection rates up to 22% 1
Warm, humid environments and male gender increase the risk of tinea pedis 1, 2

The American Academy of Pediatrics recommends not assuming treatment failure is drug resistance alone, as poor compliance, inadequate drug penetration, bacterial superinfection, or reinfection from nails/footwear are more common causes 3
Not treating feet in isolation, as concomitant onychomycosis (present in 25% of cases) and other body sites should be examined 2, 3

Monitoring liver function tests at baseline and during prolonged oral therapy, especially with itraconazole, is recommended 3
Follow-up to ensure treatment effectiveness and consider culture at end of treatment to confirm mycological clearance is recommended 3